A Randomised, Open-Label, Multicentre Phase 1b/2 Study of Eribulin Mesylate in Combination with PEGylated Recombinant Human Hyaluronidase in Patients (pts) with HER2-Negative, High-Hyaluronan Metastatic Breast Cancer (MBC)
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY（2017）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要